7-chloro-2,3-dihydro-4H-pyrano[2,3-b]pyridin-4-one | 1196145-79-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃吡啶类
• 英文名称: 7-chloro-2,3-dihydro-4H-pyrano[2,3-b]pyridin-4-one
• 英文别名: 7-chloro-2H-pyrano[2,3-b]pyridin-4(3H)-one；7-Chloro-2H-pyrano[2,3-B]pyridin-4(3H)-one；7-chloro-2,3-dihydropyrano[2,3-b]pyridin-4-one
• CAS: 1196145-79-5
• 化学式: C₈H₆ClNO₂
• 分子量: 183.594
• InChiKey: BOPVAHLYFVGKNB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-chloro-2,3-dihydro-4H-pyrano[2,3-b]pyridin-4-one 在 四(三苯基膦)钯 、 草酰氯 、 palladium 10% on activated carbon 、 氢气 、 potassium carbonate 、 二甲基亚砜 作用下， 以 甲醇 、 乙二醇二甲醚 、 二氯甲烷 、 水 为溶剂， -78.0~85.0 ℃ 、310.27 kPa 条件下， 反应 8.0h， 生成 7-phenethyl-2H-pyrano[2,3-b]pyridin-4(3H)-one
  参考文献：
  名称：

  Discovery of novel positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5)

  摘要：

  Novel in vitro mGlu(5) positive allosteric modulators with good potency, solubility, and low lipophilicity are described. Compounds were identified which did not rely on the phenylacetylene and carbonyl functionalities previously observed to be required for in vitro activity. Investigation of the allosteric binding requirements of a series of dihydroquinolinone analogs led to phenylacetylene azachromanone 4 (EC50 11.5 nM). Because of risks associated with potential metabolic and toxicological liabilities of the phenylacetylene, this moiety was successfully replaced with a phenoxymethyl group (27; EC50 156.3 nM). Derivation of a second-generation of mGlu(5) PAMs lacking a ketone carbonyl resulted in azaindoline (33), azabenzimidazole (36), and N-methyl 8-azaoxazine (39) phenylacetylenes. By scoping nitrogen substituents and phenylacetylene replacements in 39, we identified phenoxymethyl 8-azaoxazine 47 (EC50 50.1 nM) as a potent and soluble mGlu(5) PAM devoid of both undesirable phenylacetylene and carbonyl functionalities. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.027
• 作为产物：
  描述：

  2,6-二氯吡啶 在 草酰氯 、 sodium hydride 、 三乙胺 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 二氯甲烷 、 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 7-chloro-2,3-dihydro-4H-pyrano[2,3-b]pyridin-4-one
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS AS HPK1 INHIBITORS
  [FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE HPK1

  摘要：

  本文提供了作为 HPK1 抑制剂的杂环化合物，特别是式 I 的化合物或其药学上可接受的盐，以及包含所述化合物的药物组合物，可用于治疗 HPK1 介导的疾病和病症，如癌症。

  公开号：

  WO2022188735A1

文献信息

• ALPHA, BETA-UNSATURATED AMIDE COMPOUND
  申请人：Kyowa Kirin Co., Ltd.

  公开号：EP3712129A1

  公开（公告）日：2020-09-23

  An object of the present invention is to provide an α,β-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like. The α,β-unsaturated amide compound represented by the following formula (I) or a pharmaceutically acceptable salt or the like thereof has anticancer activity and the like: [wherein, "A" represents optionally substituted heterocyclic diyl, R1 represents hydrogen atom or optionally substituted lower alkyl, R2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents -O-, -S-, -SO2-, -NRX1- (wherein, RX1 represents hydrogen atom or lower alkyl), -CHRX2- (wherein, RX2 represents hydrogen atom or hydroxy), -CH=CH-, -CO- or -NH-CO-, and n1 and n2 are the same or different, and each represents 0 or 1].

  本发明的目的是提供一种具有抗癌活性的α，β-不饱和酰胺化合物或其药学上可接受的盐或类似物。下式（I）代表的α，β-不饱和酰胺化合物或其药学上可接受的盐或类似物具有抗癌活性等： [其中，"A "代表任选取代的杂环二基、 R1 代表氢原子或任选取代的低级烷基、 R2 代表任选取代的芳基、任选取代的环烷基、任选取代的脂肪杂环基团或任选取代的芳香杂环基团、 X代表-O-、-S-、-SO2-、-NRX1-（其中，RX1代表氢原子或低级烷基）、-CHRX2-（其中，RX2代表氢原子或羟基）、-CH=CH-、-CO-或-NH-CO-，以及 n1 和 n2 相同或不同，且各自代表 0 或 1]。
• EP3712129
  申请人：——

  公开号：——

  公开（公告）日：——
• Alpha,Beta-UNSATURATED AMIDE COMPOUND
  申请人：KYOWA KIRIN CO., LTD.

  公开号：US20210155612A1

  公开（公告）日：2021-05-27

  An object of the present invention is to provide an α,β-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like. The α,β-unsaturated amide compound represented by the following formula (I) or a pharmaceutically acceptable salt or the like thereof has anticancer activity and the like: [wherein, “A” represents optionally substituted heterocyclic diyl, R 1 represents hydrogen atom or optionally substituted lower alkyl, R 2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents —O—, —S—, —SO 2 —, —NR X1 — (wherein, R X1 represents hydrogen atom or lower alkyl), —CHR X2 — (wherein, R X2 represents hydrogen atom or hydroxy), —CH═CH—, −CO— or —NH—CO—, and n1 and n2 are the same or different, and each represents 0 or 1].
• Discovery of novel positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5)
  作者：Jeffrey G. Varnes、Andrew P. Marcus、Russell C. Mauger、Scott R. Throner、Valerie Hoesch、Megan M. King、Xia Wang、Linda A. Sygowski、Nathan Spear、Reto Gadient、Dean G. Brown、James B. Campbell

  DOI：10.1016/j.bmcl.2011.01.027

  日期：2011.3

  Novel in vitro mGlu(5) positive allosteric modulators with good potency, solubility, and low lipophilicity are described. Compounds were identified which did not rely on the phenylacetylene and carbonyl functionalities previously observed to be required for in vitro activity. Investigation of the allosteric binding requirements of a series of dihydroquinolinone analogs led to phenylacetylene azachromanone 4 (EC50 11.5 nM). Because of risks associated with potential metabolic and toxicological liabilities of the phenylacetylene, this moiety was successfully replaced with a phenoxymethyl group (27; EC50 156.3 nM). Derivation of a second-generation of mGlu(5) PAMs lacking a ketone carbonyl resulted in azaindoline (33), azabenzimidazole (36), and N-methyl 8-azaoxazine (39) phenylacetylenes. By scoping nitrogen substituents and phenylacetylene replacements in 39, we identified phenoxymethyl 8-azaoxazine 47 (EC50 50.1 nM) as a potent and soluble mGlu(5) PAM devoid of both undesirable phenylacetylene and carbonyl functionalities. (C) 2011 Elsevier Ltd. All rights reserved.